News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Lucid Files IPO For Up To $28.8M To Repay Debt, Expand Business
April 19, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WSJ -- Lucid Inc. filed plans to sell up to $28.8 million of common stock in an initial public offering, as the medical-device maker seeks to raise money to repay debt and build its global research and sales.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Cell therapy
Cell therapy investment grows as safety events rankle Big Pharma’s CAR T autoimmune push
November 2, 2026
·
3 min read
·
Annalee Armstrong
Drug Development
Dren Bio lands $350M to push rare blood cancer therapy toward market
October 29, 2026
·
2 min read
·
Gabrielle Masson
Immuno-oncology
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
October 28, 2026
·
2 min read
·
Tristan Manalac
IPO
2026 IPO stock tracker: How newly public biotechs are performing
October 28, 2026
·
1 min read
·
Gabrielle Masson